Insight into the role of IGF2BP1 in drug resistant mechanism of oral squamous cell carcinoma

doi:10.19439/j.sjos.2021.05.002

Abstract

Abstract: PURPOSE: This study focused on the role and mechanism of IGF2BP1 in cell cisplatin resistance of oral squamous cell carcinoma. METHODS: Low-dose intermittent induction method was used to induce cisplatin-sensitive oral squamous cell carcinoma cell line HN30, and establish cisplatin-resistant cell line HN30/DDP. Western blot was used to detect the protein expression level of IGF2BP1 in parental and resistant cell line. Knockdown or overexpression of IGF2BP1 by RNAi and lentivirus transfection method was utilized to analyze the effect of decreased or increased the gene expression of IGF2BP1 on cisplatin resistance. MTT method was used to detect the change of IC₅₀. Statistical analysis of data was performed using SPSS 17.0 software package. RESULTS: Cisplatin-resistant oral squamous cell carcinoma cell line was successfully established. The IC₅₀ of the drug-resistant cells was significantly higher than that of the parental cells. Knocking down the expression level of IGF2BP1 in drug-resistant strains reduced cell resistance; on the contrary, after overexpression of IGF2BP1 in parental cells dramatically increased cisplatin resistance. Mechanically, activation of Akt signaling pathway was the key factor mediating IGF2BP1 to promote cisplatin resistance in oral squamous cell carcinoma. CONCLUSIONS: IGF2BP1 is significantly associated with cisplatin resistance in oral squamous cell carcinoma. IGF2BP1 can promote cisplatin resistance of oral squamous cells by activating downstream Akt signaling pathway.

Key words: Oral squamous cell carcinoma, IGF2BP1, Chemotherapy resistance, Cisplatin

CLC Number:

R739.8

XIE Fei, QIN Xing, TONG Tong, JIANG Ying-ying, ZHANG Jian-jun. Insight into the role of IGF2BP1 in drug resistant mechanism of oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2021, 30(5): 456-461.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[3] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[4] Chi AC, Day TA, Neville BW.Oral cavity and oropharyngeal squamous cell carcinoma-an update[J]. CA Cancer J Clin, 2015, 65(5): 401-421.
[5] 邱蔚六. 口腔颌面部癌瘤治疗的新理念—浅析综合序列治疗[J]. 上海第二医科大学学报, 2005, 25(4): 321-324,358.
[6] 温玉明, 华成舸, 王昌美, 等. 口腔癌的综合治疗[J]. 中华口腔医学杂志, 2003, 38(1): 73-75.
[7] Huang X, Zhang H, Guo X, et al.Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer[J]. J Hematol Oncol, 2018, 11(1): 88.
[8] Bell JL, Turlapati R, Liu T, et al.IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma[J]. J Clin Oncol, 2015, 33(11): 1285-1293.
[9] Wan BS, Cheng M, Zhang L.Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer[J]. World J Gastroenterol, 2019, 25(40): 6063-6076.
[10] Elcheva IA, Wood T, Chiarolanzio K, et al.RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1[J]. Leukemia, 2019, 34(5): 1354-1363
[11] Müller S, Glaβ M, Singh AK, et al.IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner[J]. Nucleic Acids Res, 2019, 47(1): 375-390.
[12] Liu Z, Wu G, Lin C, et al.IGF2BP1 over-expression in skin squamous cell carcinoma cells is essential for cell growth[J]. Biochem Biophys Res Commun, 2018, 501(3): 731-738.
[13] Shi R, Yu X, Wang Y, et al.Expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non-small cell lung cancer[J]. Tumour Biol, 2017, 39(4): 1010428317695928.
[14] Gong F, Ren P, Zhang Y, et al.MicroRNAs-491-5p suppresses cell proliferation and invasion by inhibiting IGF2BP1 in non-small cell lung cancer[J]. Am J Transl Res, 2016, 8(2): 485-495.
[15] Rebucci M, Sermeus A, Leonard E, et al.miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1[J]. Mol Cancer, 2015, 14(1): 79-85.
[16] Qin X, Sun L, Wang J.Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway[J]. Cell Biol Int, 2017, 41(10): 1110-1118.
[17] Faye MD, Beug ST, Graber TE, et al.IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1[J]. Oncogene, 2015, 34(12): 1532-1541.
[18] Galanski M.Recent developments in the field of anticancer platinum complexes[J]. Recent Pat Anticancer Drug discov, 2006, 1(2): 285-295.
[19] Dasari S, Tchounwou PB.Cisplatin in cancer therapy: molecular mechanisms of action[J]. Eur J Pharmacol, 2014, 740: 364-378.
[20] Shen DW, Pouliot LM, Hall MD, et al.Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes[J]. Pharmacol Rev, 2012, 64(3): 706-721.
[21] Scanlon KJ, Kashani-Sabet M, Tone T, et al.Cisplatin resistance in human cancers[J]. Pharmacol Ther, 1991, 52(3): 385-406.
[22] Crul M, Schellens JH, Beijnen JH, et al.Cisplatin resistance and DNA repair[J]. Cancer Treat Rev, 1997, 23(5-6): 341-366.
[23] Galluzzi L, Senovilla L, Vitale I, et al.Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15): 1869-1883.
[24] Wang SS, Lv Y, Xu XC, et al.Triptonide inhibits human nasopharyngeal carcinoma cell growth via disrupting Lnc-RNA THOR-IGF2BP1 signaling[J]. Cancer Lett, 2019, 443: 13-24.
[25] Kim T, Havighurst T, Kim K, et al.Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAF inhibitors[J]. Mol Carcinog, 2018, 57(5): 678-683.
[26] Ali AY, Farrand L, Kim JY, et al.Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum[J]. Ann N Y Acad Sci, 2012, 1271(1): 58-67.
[27] Fraser M, Bai T, Tsang BK.Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function[J]. Int J Cancer, 2008, 122(3): 534-546.
[28] Fraser M, Leung B M, Yan X, et al.p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells[J]. Cancer Res, 2003, 63(21): 7081-7088.
[29] Freudlsperger C, Horn D, Weiβfuβ S, et al.Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma[J]. Int J cancer, 2015, 136(12): 2775-2785.
[30] Avan A, Narayan R, Giovannetti E, et al.Role of Akt signaling in resistance to DNA-targeted therapy[J]. World J Clin Oncol, 2016, 7(5): 352-369.
[31] Sun D, Wang J, Zhang H, et al.MK2206 Enhances cisplatin-induced cytotoxicity and apoptosis in testicular cancer through Akt signaling pathway inhibition[J]. Transl Oncol, 2020, 13(7): 100769.
[32] Sun D, Sawada A, Nakashima M, et al. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway [J]. Urol Oncol, 2015, 33(3): 111.e117-111.e126.